Effect of 5-fluorouracil on G1 phase cell cycle regulation in oral cancer cell lines

Oral Oncology

Volumn 40, Issue 1, 2004, Pages 63-70

  Li, Ming Heng ^a   Ito, Daisuke ^a   Sanada, Misaki ^a   Odani, Takeshi ^a   Hatori, Masashi ^a   Iwase, Masayasu ^a   Nagumo, Masao ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

5 FU; CDK inhibitors (CKIs); Cyclin; Cyclin dependent kinases (CDKs)

Indexed keywords

CYCLIN D; CYCLIN E; FLUOROURACIL; PROTEIN P21; PROTEIN P23;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; UPREGULATION;

EID: 0344665713     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(03)00136-2     Document Type: Article

References (28)

1. Dimery I.W., Hong W.K. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst. 85:1993;95-111.
2. Kusunoki M., Yanagi H., Kotera H., Noda M., Yamamura T. Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. Int J Oncol. 13:1998;653-657.
3. Poon M.A., O'Connell M.J., Moertel C.G., Wieand H.S., Cullinan S.A., Everson L.K.et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 7:1989;1407-1418.
4. Lewin F., Skog S., Tribukait B., Ringborg U. Effect of combined treatment with cisplatin and 5-fluorouracil on cell growth and cell cycle kinetics of a mouse ascites tumor growing in vivo. In vivo. 4:1990;277-282.
5. Fujii S., Fukushima M., Shimamoto Y., Shirasaka T. Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil. Jpn. J. Cancer Res. 80:1989;509-512.
6. Mika K., Shuji N., Kenji M., Ichiro I., Keizo A., Minoru N.et al. In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line. Cancer Chemotherapy and Pharmacology. 29:1992;273-276.
7. Pinedo H.M., Peters G.F. Fluorouracil. biochemistry and pharmacology J Clin Oncol. 6:1988;1653-1664.
8. Santi D.V., McHenry C.S., Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry. 13:1974;471-481.
9. Eidelberger C., Danenberg P.V., Moran R.G. Fluorinated pyrimidines and their nucleosides. Adv. Enzymo.l Relat. Areas Mol Biol. 54:1983;58-119.
10. Myers C.E. The pharmacology of the fluoropyrimidines. Pharmacol Rev. 33:1981;1-15.
11. Maybaum J., Ullman B., Mandel H.G., Day J.L., Sadee W. Regulation of RNA- and DNA-direct actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res. 40:1980;4209-4215.
12. Lewin F., Skog S., Tribukait B., Ringborg U. Effect of 5-fluorouracil on the cell growth and cell cycle kinetics of a mouse ascites tumor growing in vivo. Acta Oncol. 26:1987;125-131.
13. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
14. Sherr C.J., Roberts J.M. CDK inhibitors. positive and negative regulators of G1 phase progression Genes Dev. 13:1999;1501-1512.
15. Morgan D.O. Principles of CDK regulation. Nature. 374:1995;131-134.
16. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., Kim S.H. Crystal structure of cyclin-dependent kinase 2. Nature. 363:1993;595-602.
17. Ma Y., Prigent S.A., Born T.L., Monell C.R., Feramisco J.R., Bertolaet B.L. Microinjection of anti-p21 antibodies induces senescent Hs68 human fibroblasts to synthesize DNA but not to divide. Cancer Res. 59:1999;5341-5348.
18. Gartel A.L., Goufman E., Tevosian S.G., Shih H., Yee A.S., Tyner A.L. Activation and repression of p21 (WAF1/CIP1) transcription by RB binding proteins. Oncogene. 17:1998;3463-3469.
19. Eapen A.K., Henry M.K., Quelle D.E., Quelle F.W. DNA damage-induced G (1) arrest in hematopoietic cells is overridden following phosphatidylinositol 3-kinase-dependent activation of cyclin-dependent kinase 2. Mol. Cell. Biol. 21:2001;6113-6121.
20. Guan K.L., Jenkins C.W., Li Y., Nichols M.A., Wu X., O'Keege C.L.et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8:1994;2939-2952.
21. Franklin D.S., Xiong Y. Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. Mol. Biol. Cell. 7:1996;1587-1599.
22. Fujii S., Shimamoto Y., Ohshimo H., Imaoka T., Motoyama M., Fukushima M.et al. Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats. Jpn. J. Cancer Res. 80:1989;167-172.
23. Pizzorno G., Sun Z., Handschumacher R.E. Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem. Pharmacol. 49:1995;553-557.
24. Shinomiya N., Takemura T., Iwamoto K., Rokutanda M. Caffeine induces S-phase apoptosis in cis-diamminedichloroplatinum-treated cells, whereas cis-diamminedichloroplatinum induces a block in G2/M. Cytometry. 27:1997;365-373.
25. Lane D.P. Cancer. p53, guardian of the genome. Nature. 358:1992;15-16.
26. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M.et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
27. El-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J.et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
28. Jiang H., Lin J., Su Z.Z., Collart F.R., Huberman E., Fisher P.B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene. 9:1994;3397-3406.